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PVIEWPOINT AND COMMENTARY
Routine Screening for Depression
in Patients With Coronary Heart Disease
Never Mind
Roy C. Ziegelstein, MD,* Brett D. Thombs, PHD,† James C. Coyne, PHD,‡ Peter de Jonge, PHD§
Baltimore, Maryland; Montreal, Quebec, Canada; Philadelphia, Pennsylvania;
and Groningen and Tilburg, the Netherlands
A recent Science Advisory from the American Heart Association (AHA) recommended routine screening of all
patients with coronary heart disease (CHD) for depression. The authors of the advisory noted that the high preva-
lence of depression in patients with CHD supports this strategy. A systematic review of the evidence on depres-
sion screening and treatment in CHD patients published soon after the AHA advisory found that screening tools
for major depression are reasonably accurate among patients with CHD, but that the majority of patients who
screen positive will not have major depression; that depression treatment in CHD patients only accounts for a
small amount of variance in depression symptom change scores; and that there is no evidence that screening
for depression improves CHD outcomes. We call for the AHA to reassess their recommendations in light of this
systematic review and considering the potential impact of their document on clinical practice. (J Am Coll
Cardiol 2009;54:886–90) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.082c
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fi“What is all this fuss I hear about the
American Heart Association recommending
screening depressed people for heart disease?”
e can imagine Emily Litella, the character played by the
ate Gilda Radner on the American comedy program
aturday Night Live in the late 1970s, looking through her
eading glasses and commenting on this news item from the
merican Heart Association (AHA) (1). The character of
mily Litella was a hard-of-hearing elderly woman, frump-
ly dressed, who provided commentary, typically in an
gitated fashion, on some news item that either excited or
pset her. Emily Litella always seemed to misunderstand
ome aspect of the news item with outrageously funny
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009, accepted January 25, 2009.onsequences, each time leading her to turn to the audience
nd meekly offer her trademark response, “Never mind.”
We can almost hear Emily commenting animatedly,
itting at the news desk looking at the camera straight on:
It’s about time. Finally, the AHA recognized that patients
ith major depression are at increased risk of developing
oronary heart disease (CHD) and called for screening of all
epressed patients for CHD and cardiovascular risk factors.”
mily would continue her thoughts about why this recom-
endation makes good sense. “CHD is quite common in
atients with major depression. Among 4,041 patients with
ajor depression in the STAR*D (Sequenced Treatment
lternatives to Relieve Depression) study, 14.3% had co-
orbid cardiac disease (2). Three separate publications
3–5) found that depressed individuals are more than 1.6
imes as likely to develop CHD compared with individuals
ithout depression. Individuals with depression are more
ikely to smoke cigarettes (6) and to be physically inactive
7) compared with those without depression. It also seems
hat enhanced platelet activation in depressed patients may
ncrease their susceptibility to cardiac events (5). Some have
uggested that chronic dysregulation of the hypothalamic-
ituitary-adrenal axis found in patients with depression may
ead to the development of cardiovascular risk factors and an
ncreased susceptibility to cardiac disease (8). Whatever the
ause, the prevalence and importance of CHD in patients
ith major depression are reason enough for the AHA to
nally call for routine screening for CHD in depressed
atients. I hope that psychiatrists and primary care physi-
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hat all of their depressed patients get screening for heart
isease.”
At this point, the news anchor would interrupt Emily and
ote that she got it backward: the AHA actually did not
ecommend screening depressed people for heart disease,
ut rather recommended screening all heart disease patients
or depression (1). Deflated, Emily Litella would look at the
amera and say, “Never mind.” And we want to say the same
bout the AHA’s call for routine screening for depression in
atients with CHD. Never mind . . . . at least not yet. The
ecent call for routine screening for depression in patients
ith CHD is premature and not supported by existing
vidence.
So how could it be that we, a group of people who have
een calling for cardiologists to pay more attention to
epression, are now saying, “Never mind?” To some extent,
he AHA workgroup recommendation represents a call for
reater attention to depression in patients with heart dis-
ase. And in that regard, nothing could make us happier. It
hows just how far this field has come in the last 15 years or
o. But greater attention and routine screening are 2
ifferent things. Providing good clinical care by talking to
atients, and when appropriate, discussing whether they
ave symptoms of depression that might benefit from
reatment is different from routinely screening all CHD
atients using questionnaires or surveys. Several factors
ust apply for screening to be a reasonable strategy, but the
rincipal criterion is that there must be sufficient evidence
hat the benefits from screening substantially outweigh
otential harms (9). There is simply insufficient evidence
hat this criterion has been met yet with respect to depres-
ion screening in CHD patients.
Lichtman et al. (1) rationalize their call for routine
creening primarily by noting that depression is important
nd prevalent in patients with CHD. Although these are
ecessary criteria to recommend screening, they are not
ufficient. If that were all that were needed, we would screen
ll CHD patients for aortic dissection or pulmonary embo-
ism (important), for diverticular disease (common), or for
arotid stenosis (important and common). A disappointing
spect of the call for routine screening by Lichtman et al. (1)
s that they seem to lump together the desire to generate
ncreased awareness of depression and depression screening.
he investigators (1) note, “In summary, the high preva-
ence of depression in patients with CHD supports a
trategy of increased awareness and screening for depression
n patients with CHD” (p. 1771). However, being more
ware of a condition is not the same as routinely screening
or it. By becoming familiar with the signs and symptoms of
condition, and by recognizing its prevalence and impor-
ance, a clinician may be more likely to diagnose a patient
ho has that condition. Greater understanding of, familiar-
ty with, and attention to a health problem such as depres-
ion, however, is quite different from routinely using a
epression screening instrument for all patients. bFor routine screening of CHD
atients for depression to be rec-
mmended, screening instru-
ents must be sufficiently sensi-
ive and specific in patients with
HD so that patients with de-
ression are recognized while at
he same time patients without
epression are not inappropri-
tely identified as being de-
ressed. Our recent systematic
eview (10) found that screening
nstruments in cardiovascular disease settings perform sim-
larly to instruments in primary care settings (11) (median
ensitivity 84%, median specificity 79%). We found that
here were few instruments or cutoff scores validated in
ore than 1 sample, however, and there was evidence that
utoff scores used in primary care may not work equivalently
n patients with CHD. Based on the 15% median preva-
ence of major depression in the screening studies we
eviewed, 304 of every 1,000 patients would screen positive
nd need further evaluation, and only 126 (41%) of these
ould have major depression. The investigators (1) of the
cientific advisory suggest that “patients with screen-
ng scores that indicate a high probability of depres-
ion. . .should be referred for a more comprehensive clinical
valuation by a professional qualified to evaluate and deter-
ine a suitable individualized treatment plan” (p. 1770). It
s not clear what is meant by “high probability” in this
tatement, however, because an individual with a positive
epression screen in the studies that we examined would
ctually have a greater chance of not having major depres-
ion than of having this condition.
For screening to improve clinical care, treatment of
epression in patients with cardiovascular disease must be
elivered effectively, and it would be ideal if treatment of
epression would reliably improve cardiovascular disease
utcomes as well. Our systematic review of the literature
10) showed that there is evidence that treatment of
epression is associated with modest improvement of de-
ression in CHD patients. However, depression treatment
n CHD patients only accounts for 1% to 4% of the variance
n depression symptom change scores, and there is no
vidence that screening for depression improves CHD
utcomes. Lichtman et al. (1) seem to think that the
bsence of demonstrated benefit on CHD outcomes is
nimportant. They contend, “Thus whether depression
mpacts cardiac outcomes directly or indirectly, the need to
creen and treat depression is imperative” (p. 1769). And
lsewhere, the investigators note, “Although there is cur-
ently no direct evidence that screening for depression leads
o improved outcomes in cardiovascular populations. . .it is
mportant to assess depression in cardiac patients with the
oal of targeting those most in need of treatment and
upport services” (p. 1770). Again, the investigators seem to
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
CHD  coronary heart
disease
USPSTF  U.S. Preventive
Services Task Forcelur any distinction between assessing depression and rou-
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Depression Screening in Cardiovascular Disease September 1, 2009:886–90inely screening for it, and they sweep aside the lack of
vidence as being unimportant.
For follow-up, Lichtman et al. (1) indicate, “Patients
ith positive screening results should be evaluated by a
rofessional qualified in the diagnosis and management of
epression” (p. 1771). Given the paucity of evidence show-
ng that this would result in improvement of depressive
ymptoms and the lack of evidence that it would improve
ardiac outcomes, this recommendation must be considered
ery carefully. Unless cardiologists can become professionals
qualified in the diagnosis and management of depression,”
he most likely outcome would be a reliance on referral to
rimary care physicians, the de facto context for most care
or depression. Yet, in primary care, few depressed patients
eceive an adequate course of treatment, with a majority of
hose who are prescribed antidepressant medications dis-
ontinuing shortly after these drugs are initiated (12–15). It
s estimated that only 20% to 30% of depressed people being
reated exclusively in primary care settings receive adequate
are and follow-up (16,17), and it is unlikely that the
ituation would be better in cardiovascular disease settings.
For routine screening to be recommended, there must be
ufficient evidence that it does not lead to significant harms
hat outweigh potential benefits. And here, we are operating
n a black box with respect to routine depression screening
n patients with CHD. Whether routine depression screen-
ng of patients with CHD might lead to inappropriate
abeling and treatment on the one hand, or on the other
and to extraordinary and impractical overuse of important
ealth care resources to avoid it, has not been examined, and
he potential for such harm is quite real.
Indeed, the costs of introducing routine screening for
epression without additional resources are potentially sub-
tantial. At the systems level, routine screening may divert
xisting mental health resources away from what already
esults in less than adequate care and follow-up of patients
ith depression and cardiovascular disease (16,17). Argu-
bly, the quality of routine care should be substantially
mproved before undertaking initiatives that may result in
he entry of more patients into the pipeline. Furthermore,
ithout sufficient mental health resources to ensure ade-
uate care and follow-up, cardiologists may begin patients
n antidepressant medications simply on the basis of a
ositive depression screen, believing that scores on screening
nstruments like the 9-item depression scale of the Patient
ealth Questionnaire are sufficient for clinical decision
aking (18). Practices like this may result in labeling
atients as depressed when they do not have this condition,
nd in their being unnecessarily exposed to the risks of
ntidepressant medications without the potential benefit. It
hould be noted that already in some populations the
revalence of antidepressant prescriptions equals or exceeds
he presumed prevalence of major depression (19,20), even
hen the majority of patients who actually have depression
re untreated (21). Inappropriate labeling and treatment
ay result in an increased risk of stigma, which has been cbserved to be associated with greater unmet mental health
are needs rather than increasing the chance that patients
ill receive and benefit from treatment (22–24).
Guidelines and recommendations are sometimes made
ithout full consideration of evidence or clinical practice
ealities. For instance, even highly conservative estimates
ave found that primary care physicians would need more
han 7 h per working day to provide recommended preven-
ive services to an average patient panel (25). With depres-
ion screening in cardiovascular care settings, we have a
roup of physicians (cardiologists) who generally have
either the expertise nor the time to screen or to handle the
esults of screening and a system ill prepared to guarantee
ompletion of or referral to effective care. If the AHA calls
or screening for depression are not simply ignored, imple-
entation of routine screening may result in overtreatment
f depression because of the prescription of antidepressant
edications based on positive screens without follow-up
iagnostic interviews on the one hand, and inadequate
reatment of CHD patients with major depression on the
ther.
The U.S. Preventive Services Task Force (USPSTF)
akes recommendations about screening for conditions
uch as high blood pressure and asymptomatic carotid artery
tenosis that might otherwise not be recognized as part of
sual care. It is useful to look at how the USPSTF handles
hese 2 conditions, both of which are unquestionably
revalent and important in adults. The USPSTF (26)
ecently recommended screening for high blood pressure in
dults, noting that “. . . certainty is high that the net benefit
f screening for high blood pressure in adults is substantial”
p. 783). On the other hand, with respect to screening for
arotid artery stenosis in asymptomatic individuals, the
SPSTF (27) concluded that there is “. . . moderate cer-
ainty that the benefits of screening do not outweigh the
arms” (p. 855). We believe that the AHA workgroup’s
ecommendation for routine screening for depression in
atients with CHD is premature because a similarly rigor-
us assessment of risks and benefits was not performed. The
HA workgroup made these recommendations without
areful consideration of existing evidence. Based on our
ystematic review of the literature (10), evidence of the
enefit of this strategy cannot be found . . . at least not at
he present time.
The AHA is an outstanding organization that guides the
ractice of many cardiologists and other practitioners
round the world. It is because of this impact that we hope
hat the AHA reconsiders its recommendation, at least at
his time. Recently, the AHA reconsidered its 50-year-old
ecommendation for antibiotic prophylaxis against infective
ndocarditis for patients with certain cardiac conditions,
oncluding that their own prior guidelines were not based
n sufficient evidence (28). The AHA went as far as noting,
Although it has long been assumed that dental procedures
ay cause infective endocarditis in patients with underlyingardiac risk factors and that antibiotic prophylaxis is effec-
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September 1, 2009:886–90 Depression Screening in Cardiovascular Diseaseive, scientific proof is lacking to support these assumptions”
p. 1744). This was a bold move, and one we applaud.
ecently, the joint American College of Cardiology
ACC)/AHA guidelines on perioperative cardiovascular
valuation for noncardiac surgery (29) were criticized based
n the argument that the recommendation for perioperative
eta-blocker therapy is not supported by the current body of
vidence (30). It has been pointed out that despite this, the
ndorsement of the AHA and ACC led the Physicians
onsortium for Performance Improvement and the Surgical
are Improvement Project of the American Medical Asso-
iation to establish perioperative beta-blockade as a quality
easure (31), potentially placing practitioners who do not
ollow the guidelines at increased risk of litigation (30). In
heir criticism of the ACC/AHA recommendation for
erioperative beta-blocker therapy, Messerli and Bangalore
30) referred to the guidelines document itself (29), and
uggested that it met neither of its stated criteria that,
guidelines should be based on both rigorous and expert
nalysis of the available data documenting absolute and
elative benefits and risk of those procedures and therapies”
p. 1972) and that “guidelines . . . improve the effectiveness
f care, optimize patient’s outcomes, and favorably affect the
verall cost of care by focusing resources of the most
ffective strategies” (p. 1972). This criticism similarly ap-
lies to the recent AHA recommendations on depression
creening.
Emily Litella might have gotten the AHA’s recommen-
ation backward, but it might not have been a problem with
er hearing this time. She might have thought, as we do,
hat the recommendation for routine screening for depres-
ion in CHD patients is premature, and she might have
ssumed that it was impossible that this is what she actually
eard. Indeed, given the incontrovertible evidence that early
reatment of patients at risk for CHD improves outcomes,
here is almost more reason to consider routine screening for
HD in depressed patients than routine screening for
epression in CHD patients, at least at the present time.
e call for the AHA to reassess their recommendations in
ight of our recent systematic review (10) and considering
he potential impact of their document on clinical practice.
e suggest that the AHA consider a modified statement,
ne that emphasizes the importance of depression in pa-
ients with cardiovascular disease, raises the awareness of
ardiovascular care providers to the symptoms of emotional
llness, and suggests the development of closer clinical
elationships with mental health providers. The modified
tatement could indicate the rationale for revising their
ecent advisory by pointing out the limitations of existing
vidence, by noting that the basis for the recommendations
f the advisory was not well established, and by concluding
hat without additional evidence of the benefit of routine
creening, this is as much as can be recommended at this
ime.
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edical Center, 4940 Eastern Avenue, Baltimore, Maryland
1224-2780. E-mail: rziegel@jhmi.edu.
EFERENCES
1. Lichtman JH, Bigger JT Jr., Blumenthal JA, et al. Depression and
coronary heart disease. Recommendations for screening, referral, and
treatment. A science advisory from the American Heart Association
Prevention Committee of the Council on Cardiovascular Nursing,
Council on Clinical Cardiology, Council on Epidemiology and Pre-
vention, and Interdisciplinary Council on Quality of Care and Out-
comes Research. Circulation 2008;118:1768–75.
2. Fraguas R Jr., Iosifescu DV, Alpert J, et al. Major depressive disorder
and comorbid cardiac disease: is there a depressive subtype with greater
cardiovascular morbidity? Results from the STAR*D study. Psycho-
somatics 2007;48:418–25.
3. Wulsin LR, Singal BM. Do depressive symptoms increase the risk for
the onset of coronary disease? A systematic quantitative review.
Psychosom Med 2003;65:201–10.
4. Rugulies R. Depression as a predictor for coronary heart disease. A
review and meta-analysis. Am J Prev Med 2002;23:51–61.
5. Musselman DL, Tomer A, Manatunga AK, et al. Exaggerated platelet
activity in major depression. Am J Psychiatry 1996;153:1313–7.
6. Covey LS, Glassman AH, Stetner F. Cigarette smoking and major
depression. J Addict Dis 1998;17:35–46.
7. Allgöwer A, Wardle J, Steptoe A. Depressive symptoms, social
support, and personal health behaviors in young men and women.
Health Psychol 2001;20:223–7.
8. Jokinen, J, Nordström, P. HPA axis hyperactivity and cardiovascular
mortality in mood disorder inpatients. J Affect Disord 2009;116:88–92.
9. Sawaya GF, Guirguis-Blake J, LeFevre M, Harris R, Petitti D, for the
U.S. Preventive Services Task Force. Update on the methods of the
U.S. Preventive Services Task Force: Estimating certainty and mag-
nitude of net benefit. Ann Intern Med 2007;147:871–5.
0. Thombs BD, de Jonge P, Coyne JC, et al. Screening for depression
and cardiovascular care outcomes: a systematic review. JAMA 2008;
300:2161–71.
1. Williams JW Jr., Pignone M, Ramirez G, Perez Stellato C. Identifying
depression in primary care: a literature synthesis of case-finding
instruments. Gen Hosp Psychiatry 2002;24:225–37.
2. Akincigil A, Bowblis JR., Levin C, Walkup JG, Jan S, Crystal S.
Adherence to antidepressant treatment among privately insured pa-
tients diagnosed with depression. Med Care 2007;45:363–9.
3. Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antide-
pressants in a primary care setting, 1: beyond lack of efficacy and
adverse events. J Clin Psychiatry 2001;62:30–3.
4. Moride Y, du Fort GG, Monette J, et al. Suboptimal duration of
antidepressant treatments in the older ambulatory population of
Quebec: association with selected physician characteristics. J Am
Geriatr Soc 2002;50:1365–71.
5. Mojtabai R, Olfson M. National patterns in antidepressant treatment
by psychiatrists and general medical providers: results from the
National Comorbidity Survey Replication. J Clin Psychiatry 2008;69:
1064–74.
6. Fernandez A, Haro JM, Martinez-Alonso M, et al. Treatment
adequacy for anxiety and depressive disorders in six European coun-
tries. Br J Psychiatry 2007;190:172–3.
7. Weilburg JB, O’Leary KM, Meigs JB, Hennen J, Stafford RS.
Evaluation of the adequacy of outpatient antidepressant treatment.
Psychiatr Serv 2003;54:1233–9.
8. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a
self-report version of PRIME-MD: the PHQ primary care study.
Primary Care Evaluation of Mental Disorders. Patient Health Ques-
tionnaire. JAMA 1999;282:1737–44.
9. Esposito E, Wang JL, Adair CE, et al. Frequency and adequacy of
depression treatment in a Canadian population sample. Can J Psychi-
atry 2007;52:780–9.0. Beck CA, Patten SB, Williams JV, et al. Antidepressant utilization in
Canada. Soc Psychiatry Psychiatr Epidemiol 2005;40:799–807.
22
2
2
2
2
2
2
2
3
3
890 Ziegelstein et al. JACC Vol. 54, No. 10, 2009
Depression Screening in Cardiovascular Disease September 1, 2009:886–901. Kessler RC, Merikangas KR, Wang PS. Prevalence, comorbidity, and
service utilization for mood disorders in the United States at the
beginning of the twenty-first century. Annu Rev Clin Psychol 2007;
3:137–58.
2. Roeloffs C, Sherbourne C, Unutzer J, Fink A, Tang LQ, Wells KB.
Stigma and depression among primary care patients. Gen Hosp
Psychiatry 2003;25:311–5.
3. Sirey JA, Bruce ML, Alexopoulos GS, Perlick DA, Friedman SJ,
Meyers BS. Perceived stigma and patient-rated severity of illness as
predictors of antidepressant drug adherence. Psychiatr Serv 2001;52:
1615–20.
4. Sirey JA, Bruce ML, Alexopoulos GS, et al. Perceived stigma as a
predictor of treatment discontinuation in young and older outpatients
with depression. Am J Psychiatry 2001;158:479–81.
5. Yarnall KSH, Pollak KI, Ostbye T, Krause KM, Michener JL.
Primary care: is there enough time for prevention? Am J Public Health
2003;93:635–41.
6. U.S. Preventive Services Task Force. Screening for high blood pres-
sure: U.S. Preventive Services Task Force reaffirmation recommenda-
tion statement. Ann Intern Med 2007;147:783–6.
7. U.S. Preventive Services Task Force. Screening for carotid artery
stenosis: U.S. Preventive Services Task Force recommendation state-
ment. Ann Intern Med 2007;147:854–9. K8. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective
endocarditis: guidelines from the American Heart Association: a
guideline from the American Heart Association Rheumatic Fever,
Endocarditis, and Kawasaki Disease Committee, Council on Cardio-
vascular Disease in the Young, and the Council on Clinical Cardiol-
ogy, Council on Cardiovascular Surgery and Anesthesia, and the
Quality of Care and Outcomes Research Interdisciplinary Working
Group. Circulation 2007;116:1736–54.
9. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007
guidelines on perioperative cardiovascular evaluation and care for
noncardiac surgery: executive summary: a report of the American
College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Writing Committee to Revise the 2002 Guide-
lines on Perioperative Cardiovascular Evaluation for Noncardiac Sur-
gery). J Am Coll Cardiol 2007;50:1707–32.
0. Messerli FH, Bangalore S. When guidelines need guidance. Am J
Med 2008;121:742–3.
1. Physician Consortium for Performance Improvement and the Surgical
Care Improvement Project of the American Medical Association.
2007. Available at: http://www.ama-assn.org/ama/pub/category/
2946.html. Accessed November 10, 2008.ey Words: depression y screening y guidelines.
